ST Su Wu: Lincomycin hydrochloride injection passed the consistency evaluation of generic drugs.

ST Suwu Announcement: The wholly-owned subsidiary Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Suzhou Pharmaceutical Factory has received the National Medical Products Administration's approval and issuance of the Approval Notice for the Supplement of Lincomycin Hydrochloride Injection. This drug has passed the evaluation of generic drug quality and efficacy consistency. The total national hospital sales of Lincomycin Hydrochloride Injection in 2024 are approximately 22.1165 million yuan, with research and development expenses of approximately 3.1324 million yuan. The consistency evaluation is conducive to enhancing the market competitiveness of the drug, and will have a positive impact on the company's sales.